Search results
Fatty Liver to Cirrhosis Timeline: Prevalence, Treatment, and Outlook
Healthline· 6 days agoIt usually takes years for fatty liver disease to progress to cirrhosis, but several factors affect...
High levels of novel biomarker GDF15 in steatotic liver patients linked to increased liver cancer...
Medical Xpress· 10 hours agoThe findings are published in the journal Alimentary Pharmacology & Therapeutics. Steatotic (fatty) liver disease is on the rise in many countries around the world. A rise in steatotic liver ...
FMT Could Prevent Hepatic Encephalopathy in Cirrhosis
Medscape· 24 hours agoA phase 2 trial of fecal microbiota transplantation to prevent hepatic encephalopathy in cirrhosis...
Biotech Stock Roundup: GSK's Litigation Update, BIIB's Drug Approval & Other Updates
Zacks via Yahoo Finance· 11 hours agoOne cohort is evaluating the combination of tobevibart and elebsiran, dosed every four weeks with a...
Madrigal shares maintain Buy rating on Phase 3 MAESTRO-NASH trial By Investing.com
Investing.com· 11 hours agoAssociation for the Study of the Liver (EASL) Congress, where Madrigal unveiled new data from its...
...the WIND-PSC Study, a Global Prospective Cohort to Support the Development of New Treatments for...
Benzinga· 3 days agoPSC Partners and PSC Partners Canada, both patient-led non-profit organizations supporting education and research in primary sclerosing cholangitis (PSC), announced today the enrollment of the ...
Sequana Medical announces data on alfapump® safety and quality of life to be presented at EASL...
Benzinga· 24 hours agoGhent, Belgium – 6 June 2024 – Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company" or "Sequana Medical"), a pioneer in the treatment of fluid overload in liver disease ...
Viking (VKTX) Falls 10% Despite Upbeat NASH Study Results
Zacks via Yahoo Finance· 2 days agoViking Therapeutics (VKTX) reports promising 52-week treatment data from a mid-stage study on its...
Gilead’s Seladelpar Demonstrated a Sustained and Consistent Long-Term Efficacy and Safety Profile in...
Morningstar· 2 days agoSciences, Inc. (Nasdaq: GILD), following the recent acquisition of CymaBay Therapeutics, Inc., today announced two-year interim results from the ongoing ASSURE study of investigational seladelpar ...
Viking Therapeutics Stock Crumbles Despite Potential 'Best-In-Class' Liver Disease Drug
Investor's Business Daily· 2 days agoMASH is the new name for NASH. In its Phase 3 study, 30% of patients who received Madrigal's drug,...